365 related articles for article (PubMed ID: 23692061)
1. Intragastric acidity and omeprazole exposure during dosing with either PA32540 (enteric-coated aspirin 325 mg + immediate-release omeprazole 40 mg) or enteric-coated aspirin 325 mg + enteric-coated omeprazole 40 mg - a randomised, phase 1, crossover study.
Miner PB; Fort JG; Zhang Y
Aliment Pharmacol Ther; 2013 Jul; 38(1):62-71. PubMed ID: 23692061
[TBL] [Abstract][Full Text] [Related]
2. PA32540 (a coordinated-delivery tablet of enteric-coated aspirin 325 mg and immediate-release omeprazole 40 mg) versus enteric-coated aspirin 325 mg alone in subjects at risk for aspirin-associated gastric ulcers: results of two 6-month, phase 3 studies.
Whellan DJ; Goldstein JL; Cryer BL; Eisen GM; Lanas A; Miller AB; Scheiman JM; Fort JG; Zhang Y; O'Connor C
Am Heart J; 2014 Oct; 168(4):495-502.e4. PubMed ID: 25262259
[TBL] [Abstract][Full Text] [Related]
3. Spaced administration of PA32540 and clopidogrel results in greater platelet inhibition than synchronous administration of enteric-coated aspirin and enteric-coated omeprazole and clopidogrel.
Gurbel PA; Bliden KP; Fort JG; Jeong YH; Shuldiner A; Chai S; Gesheff T; Antonino M; Gesheff M; Zhang Y; Tantry US
Am Heart J; 2013 Feb; 165(2):176-82. PubMed ID: 23351820
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamic evaluation of clopidogrel plus PA32540: the Spaced PA32540 With Clopidogrel Interaction Gauging (SPACING) study.
Gurbel PA; Bliden KP; Fort J; Zhang Y; Plachetka JR; Antonino M; Gesheff M; Tantry US
Clin Pharmacol Ther; 2011 Dec; 90(6):860-6. PubMed ID: 22048221
[TBL] [Abstract][Full Text] [Related]
5. Interaction of omeprazole with enteric-coated salicylate tablets.
Nefesoglu FZ; Ayanoglu-Dülger G; Ulusoy NB; Imeryüz N
Int J Clin Pharmacol Ther; 1998 Oct; 36(10):549-53. PubMed ID: 9799060
[TBL] [Abstract][Full Text] [Related]
6. Comparative bioavailability and pharmacokinetics of investigational enteric- and film-coated formulations of flurbiprofen 100-mg tablets: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy Pakistani male volunteers.
Ahmad M; Pervaiz F
Clin Ther; 2010 Mar; 32(3):607-13. PubMed ID: 20399997
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and pharmacodynamics during treatment with the omeprazole 20 mg enteric-coated tablet and 20 mg capsule in asymptomatic duodenal ulcer patients.
Thomson AB; Kirdeikis P; Lastiwka R; Röhss K; Sinclair P; Olofsson B
Can J Gastroenterol; 1997; 11(8):657-60. PubMed ID: 9459044
[TBL] [Abstract][Full Text] [Related]
8. Control of 24-hour intragastric acidity with morning dosing of immediate-release and delayed-release proton pump inhibitors in patients with GERD.
Howden CW; Ballard ED; Koch FK; Gautille TC; Bagin RG
J Clin Gastroenterol; 2009 Apr; 43(4):323-6. PubMed ID: 18758373
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the effects of immediate-release omeprazole powder for oral suspension and pantoprazole delayed-release tablets on nocturnal acid breakthrough in patients with symptomatic gastro-oesophageal reflux disease.
Castell D; Bagin R; Goldlust B; Major J; Hepburn B
Aliment Pharmacol Ther; 2005 Jun; 21(12):1467-74. PubMed ID: 15948814
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and pharmacodynamics of the antiplatelet combination aspirin (acetylsalicylic acid) plus extended-release dipyridamole are not altered by coadministration with the potent CYP2C19 inhibitor omeprazole.
Offman E; Schobelock MJ; Brickl R; VanderMaelen CP; Ehrlich J; Eisert W
Am J Cardiovasc Drugs; 2013 Apr; 13(2):113-20. PubMed ID: 23532686
[TBL] [Abstract][Full Text] [Related]
11. Clinical trial: evaluation of gastric acid suppression with three doses of immediate-release esomeprazole in the fixed-dose combination of PN 400 (naproxen/esomeprazole magnesium) compared with naproxen 500 mg and enteric-coated esomeprazole 20 mg: a randomized, open-label, Phase I study in healthy volunteers.
Miner P; Plachetka J; Orlemans E; Fort JG; Sostek M
Aliment Pharmacol Ther; 2010 Aug; 32(3):414-24. PubMed ID: 20491746
[TBL] [Abstract][Full Text] [Related]
12. The budget impact of using enteric-coated aspirin 325 mg + immediate-release omeprazole 40 mg to prevent recurrent cardiovascular events.
Zhang W; Han Y; Fort JG; Schofield D; Tursi JP
J Med Econ; 2017 Jun; 20(6):592-598. PubMed ID: 28145783
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and relative bioavailability of a fixed-dose combination of enteric-coated naproxen and non-enteric-coated esomeprazole magnesium.
Wang-Smith L; Fort J; Zhang Y; Sostek M
J Clin Pharmacol; 2012 May; 52(5):670-80. PubMed ID: 21628602
[TBL] [Abstract][Full Text] [Related]
14. PA tablets: investigational compounds combining aspirin and omeprazole for cardioprotection.
Bliden KP; Brener M; Gesheff MG; Franzese CJ; Tabrizchi A; Tantry U; Gurbel PA
Future Cardiol; 2013 Nov; 9(6):785-97. PubMed ID: 24180537
[TBL] [Abstract][Full Text] [Related]
15. Usefulness of PA32540 in Protecting the Gastric Layer While Providing Secondary Prevention for Coronary Artery Disease.
Kagolanu D; Sayedy N; Haseeb S; Shah S; Lam P; Munnangi S; Viswanathan P; Stephenson K
Am J Cardiol; 2017 Oct; 120(7):1118-1121. PubMed ID: 28803655
[TBL] [Abstract][Full Text] [Related]
16. Long-Term Safety of a Coordinated Delivery Tablet of Enteric-Coated Aspirin 325 mg and Immediate-Release Omeprazole 40 mg for Secondary Cardiovascular Disease Prevention in Patients at GI Risk.
Goldstein JL; Whellan DJ; Scheiman JM; Cryer BL; Eisen GM; Lanas A; Fort JG
Cardiovasc Ther; 2016 Apr; 34(2):59-66. PubMed ID: 26725920
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic Study of Enteric-Coated Sustained-Release Aspirin Tablets in Healthy Chinese Participants.
Cong D; Qi W; Liu X; Xu X; Dong L; Xue W; Li K
Drug Des Devel Ther; 2023; 17():2421-2429. PubMed ID: 37614377
[TBL] [Abstract][Full Text] [Related]
18. Aspirin Use in Secondary Cardiovascular Protection and the Development of Aspirin-Associated Erosions and Ulcers.
Goldstein JL; Scheiman JM; Fort JG; Whellan DJ
J Cardiovasc Pharmacol; 2016 Aug; 68(2):121-6. PubMed ID: 27002280
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of a new immediate-release compound omeprazole capsule and its comparison with the enteric-coated formulation under fasting and fed conditions.
Liu Z; Ding L; Zhong S; Cao X; Jiang L; Duan H
Drug Res (Stuttg); 2013 Jul; 63(7):370-5. PubMed ID: 23558602
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic and pharmacodynamic profiles of a novel phospholipid-aspirin complex liquid formulation and low dose enteric-coated aspirin: results from a prospective, randomized, crossover study.
Franchi F; Schneider DJ; Prats J; Fan W; Rollini F; Been L; Taatjes-Sommer HS; Bhatt DL; Deliargyris EN; Angiolillo DJ
J Thromb Thrombolysis; 2022 Oct; 54(3):373-381. PubMed ID: 36036856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
